Sebastian Hummel

Managing Associate

Munich

Sebastian focuses on venture capital, growth capital and M&A transactions with particular expertise in the Life Sciences & HealthTech sector, where he advises across the full spectrum from early-stage start-ups to established scale-ups and their investors.

Sebastian represents German and international financial investors, strategic investors, technology companies and founder teams throughout the investment lifecycle.

His transaction experience spans venture capital and growth equity financing rounds, strategic partnerships, licensing arrangements, and exit transactions. Within the Life Sciences & HealthTech space, he has advised on numerous venture capital transactions, cross-border investments, and complex corporate restructurings for companies developing innovative therapeutics, medical devices, digital health solutions, and healthcare technology platforms.

His broader corporate practice encompasses corporate governance matters, the structuring of management and employee shareholdings including sophisticated equity incentive programs, venture debt arrangements, and ongoing corporate advisory work for high-growth technology companies. Sebastian regularly supports clients in navigating the regulatory complexities specific to life sciences transactions and helps structure deals that accommodate the unique risk profiles and longer development timelines characteristic of the sector.

Prior to joining Orrick, Sebastian practiced with leading international law firms, where he gained extensive cross-border transaction experience and developed deep sector knowledge in the Life Sciences & HealthTech space.

  • His recent engagements include the following projects and transactions:

    • A German biotech company on record-breaking Series C financing to advance next-generation therapies and expand international clinical development*
    • A Luxembourg-based investment firm on strategic growth investment in a German software provider serving municipal and utility sectors*
    • A Belgian lead investor on Series B financing supporting a German space and climate-tech start-up’s global expansion*
    • A German health-tech company on a financing round in the three-digit million-dollar range, supporting product innovation and international scaling*
    • Sellers of a German biotech company on strategic acquisition by a global Danish pharmaceutical leader*
    • A German biotech company on a Series B2 financing in the three-digit million-euro range to accelerate clinical development of oncology assets*
    • A German fitness-technology provider on a growth financing in the three-digit million-euro range to strengthen market position and expand digital ecosystem*
    • Shareholders of a German digital advertising company on their exit to a private investment group*
    • A German biotech company on a Series B financing in the mid double-digit million-euro range to advance novel therapeutic platform development*
    • A German sports-tech company on acquisition of a French corporate-fitness platform to expand its wellness network*
    • A German digital insurer on cross-border merger with French insurtech to form a unified European platform*
    • Shareholders of a German biotech company on sale to a U.S.-based life sciences acquirer*
    • A German biotech company on a Series B financing in the mid double-digit million-euro range to support development of cardiovascular therapeutics*
    • A German manufacturing-tech start-up on strategic investment by an industry association*
    • A German biotech company on a Series A financing in the mid double-digit million-euro range, one of Germany’s largest early-stage biotech rounds.*

    *Experience prior to joining Orrick